Opexa Commences Phase IIb Multiple Sclerosis Study
Reports Positive Phase I/II Data.
Opexa Therapeutics, Inc., a company involved in the development and commercialisation of cell therapies, today announced a number of positive steps in the Company's development including: Its Phase IIb study with Tovaxin(TM) for the treatment of multiple sclerosis has begun.
More than 90 attendees from 35 clinical sites attended the investigators' meeting held recently in The Woodlands. These sites have begun screening ...